NewsBenzingaVir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties Benzinga 2026.10.14 12:40 (GMT+0) Open on Benzinga Other news OpenAI Coming to Google Cloud: Codex Coding Agent Listed on Google Cloud Western Union Picks Noah to Settle Receiver Redirect Payouts in USDPT Securitize Will Mint Stablecoins Directly With Anchorage Digital Bank Cboe Expands U.S. Equity Options Trading Hours, Covering Popular Stocks Like Robinhood and Major ETFs OCC Finalizes GENIUS Act Stablecoin Rules Ahead of January Deadline Gate Contract Stock Zone First Launches Contract Trading, Trading Bots, and Copy Trading for FASTRETAILING (Fast Retailing 9983) and 3 Others
Cboe Expands U.S. Equity Options Trading Hours, Covering Popular Stocks Like Robinhood and Major ETFs
Gate Contract Stock Zone First Launches Contract Trading, Trading Bots, and Copy Trading for FASTRETAILING (Fast Retailing 9983) and 3 Others
